Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Immunoinformatic Analysis of SARS-CoV-2 Nucleocapsid Protein and Identification of COVID-19 Vaccine Targets

Full text
Author(s):
Oliveira, Sergio C. [1, 2] ; de Magalhaes, Mariana T. Q. [1] ; Homan, E. Jane [3]
Total Authors: 3
Affiliation:
[1] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Bioquim & Imunol, Belo Horizonte, MG - Brazil
[2] Minist Ciencia & Tecnol MCT, Conselho Nacl Desenvolvimento Cient & Tecnol CNPq, Inst Nacl Ciencia & Tecnol Doencas Trop INCT DT, Salvador, BA - Brazil
[3] IoGenetics LLC, Madison, WI - USA
Total Affiliations: 3
Document type: Journal article
Source: FRONTIERS IN IMMUNOLOGY; v. 11, OCT 28 2020.
Web of Science Citations: 0
Abstract

COVID-19 is a worldwide emergency; therefore, there is a critical need for foundational knowledge about B and T cell responses to SARS-CoV-2 essential for vaccine development. However, little information is available defining which determinants of SARS-CoV-2 other than the spike glycoprotein are recognized by the host immune system. In this study, we focus on the SARS-CoV-2 nucleocapsid protein as a suitable candidate target for vaccine formulations. Major B and T cell epitopes of the SARS-CoV-2 N protein are predicted and resulting sequences compared with the homolog immunological domains of other coronaviruses that infect human beings. The most dominant of B cell epitope is located between 176-206 amino acids in the SRGGSQASSRSSSRSRNSSRNSTPGSSRGTS sequence. Further, we identify sequences which are predicted to bind multiple common MHC I and MHC II alleles. Most notably there is a region of potential T cell cross-reactivity within the SARS-CoV-2 N protein position 102-110 amino acids that traverses multiple human alpha and betacoronaviruses. Vaccination strategies designed to target these conserved epitope regions could generate immune responses that are cross-reactive across human coronaviruses, with potential to protect or modulate disease. Finally, these predictions can facilitate effective vaccine design against this high priority virus. (AU)

FAPESP's process: 17/24832-6 - Development of vaccines based on recombinant BCG: Tuberculosis, Pertussis, Pneumococcus and Schistosoma
Grantee:Luciana Cezar de Cerqueira Leite
Support Opportunities: Research Projects - Thematic Grants